,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2011', 'fs': 'Jan 2011', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000E14To2AJ'}, 'Id': 'a0POZ00000E14To2AJ', 'Event_Date__c': '2011-01-01', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Jan 2011', 'Status_History__c': 'a132P000000Api0QAC'}, 'change': None}]",Jan 2011,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Recommended for funding with no priority', 'fs': 'Recommended for funding with no priority', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-dermatologicals-group-minutes-2012-11.pdf "" target=""_blank"">Hospital Pharmaceuticals Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-dermatologicals-group-minutes-2012-11.pdf "" target=""_blank"">Hospital Pharmaceuticals Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Oct 2011', 'fs': 'Oct 2011', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Hospital Pharmaceuticals Subcommittee at meeting Tuesday 4 October 2011.', 'fs': 'Clinical advice received from Hospital Pharmaceuticals Subcommittee at meeting Tuesday 4 October 2011.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000E14Tp2AJ'}, 'Id': 'a0POZ00000E14Tp2AJ', 'Event_Date__c': '2011-10-04', 'Event_Description__c': 'Clinical advice received from Hospital Pharmaceuticals Subcommittee at meeting Tuesday 4 October 2011.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-dermatologicals-group-minutes-2012-11.pdf "" target=""_blank"">Hospital Pharmaceuticals Subcommittee minutes</a>', 'Outcome__c': 'Recommended for funding with no priority', 'Formatted_Date__c': 'Oct 2011', 'Status_History__c': 'a132P000000AptvQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'fs': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'change': None}, 'Outcome': {'s': 'Not recommended for inclusion (HML)', 'fs': 'Not recommended for inclusion (HML)', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2012', 'fs': 'May 2012', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Dermatology Subcommittee at meeting Tuesday 15 May 2012.', 'fs': 'Clinical advice received from Dermatology Subcommittee at meeting Tuesday 15 May 2012.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000E14Tq2AJ'}, 'Id': 'a0POZ00000E14Tq2AJ', 'Event_Date__c': '2012-05-15', 'Event_Description__c': 'Clinical advice received from Dermatology Subcommittee at meeting Tuesday 15 May 2012.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Not recommended for inclusion (HML)', 'Formatted_Date__c': 'May 2012', 'PTAC_Comments__c': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'Status_History__c': 'a132P000000Aq2ZQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Not recommended for inclusion (HML)', 'fs': 'Not recommended for inclusion (HML)', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2012', 'fs': 'Nov 2012', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 November 2012.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 November 2012.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000E14Tr2AJ'}, 'Id': 'a0POZ00000E14Tr2AJ', 'Event_Date__c': '2012-11-08', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 November 2012.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Not recommended for inclusion (HML)', 'Formatted_Date__c': 'Nov 2012', 'Status_History__c': 'a132P000000AqDKQA0'}, 'change': None}, {'Summary': {'s': '<p>4.5\xa0\xa0\xa0\xa0The Subcommittee noted that Pharmac has received a request from the Canterbury, Hawkes Bay and Taranaki DHBs for the listing of hydrocortisone cream 0.5% on the HML. Members noted that the applicants state that the 1% hydrocortisone cream is too potent for use in facial dermatitis.\xa0</p><p>4.6\xa0\xa0\xa0\xa0\xa0The Subcommittee considered that there was a misconception that a weaker concentration of the same corticosteroid molecule would be less potent.\xa0Potency is related more to the nature of the corticosteroid molecule than dilution.\xa0</p><p>4.7\xa0\xa0\xa0\xa0\xa0The Subcommittee recommended not listing hydrocortisone 0.5% on the HML</p><p><br></p>', 'fs': '<p>4.5\xa0\xa0\xa0\xa0The Subcommittee noted that Pharmac has received a request from the Canterbury, Hawkes Bay and Taranaki DHBs for the listing of hydrocortisone cream 0.5% on the HML. Members noted that the applicants state that the 1% hydrocortisone cream is too potent for use in facial dermatitis.\xa0</p><p>4.6\xa0\xa0\xa0\xa0\xa0The Subcommittee considered that there was a misconception that a weaker concentration of the same corticosteroid molecule would be less potent.\xa0Potency is related more to the nature of the corticosteroid molecule than dilution.\xa0</p><p>4.7\xa0\xa0\xa0\xa0\xa0The Subcommittee recommended not listing hydrocortisone 0.5% on the HML</p><p><br></p>', 'change': None}, 'Published_Recommendation': {'s': '<p style=""text-align: justify;"">The Subcommittee <b>recommended</b> not listing hydrocortisone 0.5% on the Hospital Medicines List.</p><p><br></p>', 'fs': '<p style=""text-align: justify;"">The Subcommittee <b>recommended</b> not listing hydrocortisone 0.5% on the Hospital Medicines List.</p><p><br></p>', 'change': None}, 'Published_Discussion': {'s': '<p>4.5\xa0\xa0\xa0\xa0The Subcommittee noted that PHARMAC has received a request from the Canterbury, Hawkes Bay and Taranaki DHBs for the listing of hydrocortisone cream 0.5% on the HML. Members noted that the applicants state that the 1% hydrocortisone cream is too potent for use in facial dermatitis.\xa0</p><p>4.6\xa0\xa0\xa0\xa0\xa0The Subcommittee considered that there was a misconception that a weaker concentration of the same corticosteroid molecule would be less potent.\xa0Potency is related more to the nature of the corticosteroid molecule than dilution.\xa0</p><p>4.7\xa0\xa0\xa0\xa0\xa0The Subcommittee recommended not listing hydrocortisone 0.5% on the HML</p><p><br></p>', 'fs': '<p>4.5\xa0\xa0\xa0\xa0The Subcommittee noted that PHARMAC has received a request from the Canterbury, Hawkes Bay and Taranaki DHBs for the listing of hydrocortisone cream 0.5% on the HML. Members noted that the applicants state that the 1% hydrocortisone cream is too potent for use in facial dermatitis.\xa0</p><p>4.6\xa0\xa0\xa0\xa0\xa0The Subcommittee considered that there was a misconception that a weaker concentration of the same corticosteroid molecule would be less potent.\xa0Potency is related more to the nature of the corticosteroid molecule than dilution.\xa0</p><p>4.7\xa0\xa0\xa0\xa0\xa0The Subcommittee recommended not listing hydrocortisone 0.5% on the HML</p><p><br></p>', 'change': None}, 'Published_Application': {'s': '<p><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">The Subcommittee noted that PHARMAC has received a request from the Canterbury, Hawkes Bay and Taranaki DHBs for the listing of hydrocortisone cream 0.5% on the Hospital Medicines List.\xa0</span></p>', 'fs': '<p><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">The Subcommittee noted that PHARMAC has received a request from the Canterbury, Hawkes Bay and Taranaki DHBs for the listing of hydrocortisone cream 0.5% on the Hospital Medicines List.\xa0</span></p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2013', 'fs': 'Dec 2013', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Dermatology Subcommittee at meeting Monday 9 December 2013.', 'fs': 'Clinical advice received from Dermatology Subcommittee at meeting Monday 9 December 2013.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000E14Ts2AJ'}, 'Id': 'a0POZ00000E14Ts2AJ', 'Event_Date__c': '2013-12-09', 'Event_Description__c': 'Clinical advice received from Dermatology Subcommittee at meeting Monday 9 December 2013.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Decline', 'Summary__c': '<p>4.5\xa0\xa0\xa0\xa0The Subcommittee noted that Pharmac has received a request from the Canterbury, Hawkes Bay and Taranaki DHBs for the listing of hydrocortisone cream 0.5% on the HML. Members noted that the applicants state that the 1% hydrocortisone cream is too potent for use in facial dermatitis.\xa0</p><p>4.6\xa0\xa0\xa0\xa0\xa0The Subcommittee considered that there was a misconception that a weaker concentration of the same corticosteroid molecule would be less potent.\xa0Potency is related more to the nature of the corticosteroid molecule than dilution.\xa0</p><p>4.7\xa0\xa0\xa0\xa0\xa0The Subcommittee recommended not listing hydrocortisone 0.5% on the HML</p><p><br></p>', 'Formatted_Date__c': 'Dec 2013', 'Published_Recommendation__c': '<p style=""text-align: justify;"">The Subcommittee <b>recommended</b> not listing hydrocortisone 0.5% on the Hospital Medicines List.</p><p><br></p>', 'Published_Application__c': '<p><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">The Subcommittee noted that PHARMAC has received a request from the Canterbury, Hawkes Bay and Taranaki DHBs for the listing of hydrocortisone cream 0.5% on the Hospital Medicines List.\xa0</span></p>', 'Published_Discussion__c': '<p>4.5\xa0\xa0\xa0\xa0The Subcommittee noted that PHARMAC has received a request from the Canterbury, Hawkes Bay and Taranaki DHBs for the listing of hydrocortisone cream 0.5% on the HML. Members noted that the applicants state that the 1% hydrocortisone cream is too potent for use in facial dermatitis.\xa0</p><p>4.6\xa0\xa0\xa0\xa0\xa0The Subcommittee considered that there was a misconception that a weaker concentration of the same corticosteroid molecule would be less potent.\xa0Potency is related more to the nature of the corticosteroid molecule than dilution.\xa0</p><p>4.7\xa0\xa0\xa0\xa0\xa0The Subcommittee recommended not listing hydrocortisone 0.5% on the HML</p><p><br></p>', 'Status_History__c': 'a132P000000AqZQQA0'}, 'change': None}]",Oct 2011,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2013', 'fs': 'Dec 2013', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000E14Tt2AJ'}, 'Id': 'a0POZ00000E14Tt2AJ', 'Event_Date__c': '2013-12-09', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Dec 2013', 'Status_History__c': 'a132P000000AqZYQA0'}, 'change': None}]",Dec 2013,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2014', 'fs': 'May 2014', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000E14Tu2AJ'}, 'Id': 'a0POZ00000E14Tu2AJ', 'Event_Date__c': '2014-05-27', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'May 2014', 'Status_History__c': 'a132P000000AqhaQAC'}, 'change': None}]",May 2014,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
